GLP-1 receptor analogues (GLP-1 RAs) offer a promising therapeutic avenue, as they facilitate weight reduction, improve metabolic markers such as insulin sensitivity and lipid profiles, and also reduce the incidence of T2DM, which are more prevalent in women with PCOS. This evidence concerns the gene INS and polycystic ovary syndrome.